Autoimmune Epilepsy: Some Epilepsy Patients Harbor Autoantibodies to Glutamate Receptors and dsDNA on both Sides of the Blood-brain Barrier, which may Kill Neurons and Decrease in Brain Fluids after Hemispherotomy by Ganor, Yonatan et al.
Autoimmune Epilepsy: Some Epilepsy Patients Harbor
Autoantibodies to Glutamate Receptors and dsDNA on both
Sides of the Blood–brain Barrier, which may Kill Neurons and
Decrease in Brain Fluids after Hemispherotomy
YONATAN GANOR
a, HADASSA GOLDBERG-STERN
b,c, DINA AMROM
d, TALLY LERMAN-SAGIE
e,c, VIVIAN
I. TEICHBERG
a, DORI PELLED
f, ANTHONY H. FUTERMAN
f, BRURIA BEN ZEEV
g,c, MICHAEL FREILINGER
h,
DENIS VERHEULPEN
i, PATRICK VAN BOGAERT
i and MIA LEVITE
a,c,*
aDepartment of Neurobiology, The Weizmann Institute of Science, Rehovot, Israel;
bEpilepsy Center, Schneider Children’s Medical Center of Israel,
Petah Tiqwa, Israel;
cSackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
dDepartment of Child Neurology, Ho ˆpital Franc ¸ais-ULB,
Brussels, Belgium;
ePediatric Neurology Unit, Wolfson Medical Center, Holon, Israel;
fDepartment of Biological Chemistry, The Weizmann Institute of
Science, Rehovot, Israel;
gDepartment of Child Neurology and Epilepsy, Sheba Medical Center, Tel Hashomer, Israel;
hDepartment of Pediatrics,
University Hospital of Vienna, Austria;
iDepartment of Pediatric Neurology, ULB-Hopital Erasme, Brussels, Belgium
Purpose: Elucidating the potential contribution of speciﬁc autoantibodies (Ab’s) to the etiology and/or
pathology of some human epilepsies.
Methods: Six epilepsy patients with Rasmussen’s encephalitis (RE) and 71 patients with other
epilepsies were tested for Ab’s to the “B” peptide (amino acids 372–395) of the glutamate/AMPA
subtype 3 receptor (GluR3B peptide), double-stranded DNA (dsDNA), and additional autoimmune
disease-associated autoantigens, and for the ability of their serum and cerebrospinal-ﬂuid (CSF) to kill
neurons.
Results: Elevated anti-GluR3B Ab’s were found in serum and CSF of most RE patients, and in serum of
17/71 (24%) patients with other epilepsies. In two RE patients, anti-GluR3B Ab’s decreased drastically
in CSF following functional-hemispherotomy, in association with seizure cessation and neurological
improvement. Serum and CSF of two RE patients, and serum of 12/71 (17%) patients with other
epilepsies, contained elevated anti-dsDNA Ab’s, the hallmark of systemic-lupus-erythematosus. The
sera (but not the CSF) of some RE patients contained also clinically elevated levels of “classical”
autoimmune Ab’s to glutamic-acid-decarboxylase, cardiolipin, b2-glycoprotein-I and nuclear-antigens
SS-A and RNP-70. Sera and CSF of some RE patients caused substantial death of hippocampal
neurons.
Conclusions: Some epilepsy patients harbor Ab’s to GluR3 and dsDNA on both sides of the blood–
brain barrier, and additional autoimmune Ab’s only in serum. Since all these Ab’s may be detrimental
to the nervous system and/or peripheral organs, we recommend testing for their presence in epilepsy,
and silencing their activity in Ab-positive patients.
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INTRODUCTION
Epilepsy is a major health problem, affecting ,1% of the
worldpopulation.Therearemanydifferenttypesofepilepsy,
a substantial number with unknown etiology. Moreover,
,20–30% of all epilepsy patients are completely refractory
to all anti-epileptic drugs (AEDs) and suffer from a low
quality of life. Can autoimmunity contribute to the etiology
and/or pathology of some epilepsies ? (Rogers et al., 1994;
LeviteandHermelin,1999;Leviteetal.,1999;Wiendletal.,
2001;LeviteandHart,2002;Mantegazzaetal.,2002;Xiong
et al.,2 0 0 3 )a n dr e v i e w e db yL e v i t e( 2 0 0 2 ) .
Originally, an autoimmune process linked to speciﬁc
autoantibodies (Ab’s) to the glutamate/a-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor subtype 3 (GluR3) was suggested to underlie
only Rasmussen’s encephalitis (RE), a progressive cata-
strophic epileptic encephalopathy of unknown etiology,
causing damage primarily to one cerebral hemisphere, and
characterized by intractable unilateral focal seizures,
progressive neurological deﬁcits, and variable intellectual
impairment (Rasmussen et al., 1958). Hemispheric
atrophy, loss of cortical neurons, and chronic inﬂamma-
tory changes are characteristic of RE histopathology.
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AEDs, and the only recommended therapeutic approach is
surgical hemispherotomy, which either removes substan-
tial parts of the affected hemisphere or disconnects the
hemispheres while removing a minimal amount of cortical
structures (functional hemispherotomy) (Villemure and
Mascott, 1995).
The suggestion that the development of RE may result
from the activity of deleterious autoimmune components
in general, and speciﬁc anti-GluR3 Ab’s in particular, was
based primarily on the development of seizures and
histopathologic features mimicking RE in two (out of ﬁve)
rabbits immunized with a 212 amino-acid (aa) long
extracellular domain of GluR3 (aa 245–457) (Rogers
et al., 1994), the ﬁnding of anti-GluR3 Ab’s in some RE
patients (Rogers et al., 1994), and the beneﬁcial effect of
immunomodulatory treatment in a small number of RE
patients by repeated plasma exchange (Rogers et al.,1994;
Andrews et al., 1996) or immunoglobulin immunoabsorp-
tion (Antozzi et al., 1998), causing a transient reduction in
seizure frequency and improvement in neurological
function, in correlation with reduced serum titers of anti-
GluR3 Ab’s.
In recent years, it has become clear that anti-GluR3
Ab’s are present in some patients with other types of
epilepsy, and thus that they are by no means speciﬁc or
restricted to RE (Wiendl et al., 2001; Mantegazza et al.,
2002). Speciﬁcally, anti-GluR3 Ab’s were found in some
patients with various types of epilepsy, suffering primarily
from non-inﬂammatory focal epilepsy (Wiendl et al.,
2001), or from severe, early-onset and intractable seizures
(Mantegazza et al., 2002). Further studies and ﬁndings
suggested that anti-GluR3 Ab’s may indeed play a
pathogenic role in epilepsy, since they can: (a) bind brain
cells and structures (Levite et al., 1999; Whitney and
McNamara, 2000; Frassoni et al., 2001; Bernasconi et al.,
2002), (b) activate ionotropic GluR’s and evoke ion
currents, acting like a “novel” glutamate agonist (Twyman
et al., 1995; Levite et al., 1999; Koustova et al., 2001),
(c) kill neurons and glia cells via excitotoxicity—a fatal
overactivation of the glutamate receptors (Levite et al.,
1999; Koustova et al., 2001), alike that caused by
excess glutamate in various pathological situations
(Olney, 1990; Choi, 1992), and (d) activate the destructive
complement system within the central nervous system
(CNS), causing at ﬁrst death of astrocytes, and then death
of neurons (He et al., 1998; Whitney and McNamara,
2000). In this context it is of interest to mention that the
serial recruitment of all the complement factors in
the CNS was recently shown to induce seizures (Xiong
et al., 2003).
In addition to all the above, mice immunized with
the short GluR3-derived peptide: aa 372–395, termed
GluR3B peptide, believed to be the major antigenic
epitope of the excitotoxic anti-GluR3 Ab’s (Rogers et al.,
1994; Twyman et al., 1995), developed a brain pathology
(Levite and Hermelin, 1999; Levite et al., 1999), with
features partially resembling those found in RE patients.
Taken together, these different types of observations
suggest that anti-GluR3 Ab’s have the ability to cause
neuronal activation and death in the CNS, which could in
principal lead to the outburst of epileptic seizures. Despite
all that, the direct evidence that this occurs in vivo in
epilepsy patients is still misssing and a great deal remains
to be explored for reaching an understanding of the role of
anti-GluR3 Ab’s in epilepsy. Among the issues not studied
thus far are whether the cerebrospinal ﬂuid (CSF) levels of
anti-GluR3B Ab’s correlate with seizure frequency,
whether human anti-GluR3B rich serum or CSF have
the ability to kill neurons, and whether RE patients and
potentially other epilepsy patients harbor in addition to the
anti-GluR3 Ab’s and other anti-glutamate receptor Ab’s
(Takahashi et al., 2003), also elevated levels of other
autoimmune Ab’s of known pathogenic activity in
the periphery and CNS. These latter Ab’s could include:
anti-double-stranded (ds) DNA Ab’s, found primarily in
systemic lupus erythematosus (SLE); anti-glutamic acid
decarboxylase (GAD) Ab’s, found primarily in insulin-
dependent diabetes mellitus (IDDM) and in stiff person
syndrome; anti-cardiolipin and anti-b2 glycoprotein I
(b2GPI) Ab’s, found primarily in anti-phospholipid
syndrome (APS); and anti-nuclear Ab’s found primarily
in SLE and Sjo ¨gren’s syndrome.
In the present study, we have investigated some of these
still open issues.
METHODS
Patient Population
Rasmussen’s Encephalitis
Serum was collected from six RE patients (two males):
two from Sheba Medical Center, Israel; one from Wolfson
Medical Center, Israel; one from Centre Hospitalier
Francois Rabelais, Belgium; one from ULB-Hopital
Erasme, Belgium; and one from University Hospital of
Vienna, Austria. CSF was obtained from four of these RE
patients. The mean age of the RE patients was 10.4 years
(95% CI’s 4.1–16.6 years). Diagnosis of RE was
performed by the respective clinicians, and was based on
the presence of severalRE clinical characteristics, some of
which detected by: computerized tomography (CT),
magnetic resonance imaging (MRI), electroencephalo-
graphy (EEG), single-photon emission scan tomography
(SPECT), magnetic resonance spectroscopy (MRS) and
[18F] ﬂuorodeoxyglucose positron emission tomography
(FDG-PET).
Patients with other non-RE Types of Epilepsy
Serum was obtained from 71 consecutive age-matched
epilepsy patients during their routine visit at the
Pediatric Epilepsy Center at Schneider Children’s
Medical Center of Israel. These patients were classiﬁed
on the basis of the clinical and electrographic features of
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(Proposal for revised classiﬁcation of epilepsies and
epileptic syndromes, 1989), into 51 with partial epilepsy
(23 males, mean age 12.1 years; 95% CI’s 10.3–13.9
years) and 20 with generalized epilepsy (12 males, mean
age 10.4 years; 95% CI’s 7.5–13.2 years).
Written informed consents for sampling blood and/or
CSF were obtained from all patients or their parents/
guardians, upon approval by the Helsinki Committee at
their local institution.
Controls
Serum (49 samples) and CSF (seven samples) of
neurologically intact non-epileptic individuals were
also studied (26 males, mean age 7.2 years; 95% CI’s
5.5–8.9 years).
Detection of Anti-GluR3B and Anti-dsDNA Ab’s
Thelevelsofanti-GluR3BAb’sinseraandCSFofepilepsy
patients weretestedbyELISA,asdevelopedanddescribed
previously(LeviteandHermelin,1999;Leviteetal.,1999),
measuring in parallel the speciﬁc binding of each serum or
CSF to the GluR3B peptide (NEYERFVPFSDQQISND-
SSSSENR, synthesized at the Weizmann Institute of
Science) and the non-speciﬁc binding to bovine serum
albumin (BSA; Sigma). Speciﬁc anti-GluR3B Ab’s in
each individual was calculated as (speciﬁc binding to
GluR3B—nonspeciﬁc binding to BSA).
The levels of anti-dsDNA Ab’s were tested by ELISA,
using plates coated with Lambda phage dsDNA
(Worthington Biochemical Corporation, Lakewood, NJ,
USA) as previously described (Eilat et al., 2001).
Detection of Ab’s Directed against GAD, Cardiolipin,
b2GPI, RNP-70 and SS-A
The Ab’s against GAD, cardiolipin, b2GPI, RNP-70 and
SS-A were measured by commercial ELISA diagnostic
kits used routinely in hospitals worldwide. The clinical
evaluation was performed as instructed by the respective
manufacturer, which supplied the negative and positive
controls for each Ab type, and the exact cutoff values
above which a patient is considered positive. Speciﬁcally,
the diagnostic kits and the clinical cutoffs were as follows:
anti-GAD IgG diagnostic kit (Isletest-GAD; Biomerica,
Newport Beach, CA, USA), anti-GAD Ab’s level above
1.0 “GAD value” are considered clinically positive, and
levels of 1.0–1.05 as borderline; anti-cardiolipin and anti-
b2GPI diagnostic kits (ORG515 and ORG521; Orgentech
Diagnostika GmbH, Mainz, Germany), anti-cardiolipin
IgG levels above 10.0U/ml and anti-b2GPI levels (both
IgM and IgG) above 8.0U/ml are considered clinically
elevated, and levels of 5.0–8.0U/ml are borderline; anti-
RNP-70 and anti-SS-A IgG diagnostic kits (Medizym
anti-RNP and Medizym anti-SS-A; Medipan Diagnostica,
Selchow, Germany), anti-RNPAb’s level above 15.0U/ml
and anti-SS-A Ab’s levels above 10.0U/ml are considered
clinically elevated.
Immunostaining of Anti-nuclear Ab’s (ANA)
ANA immunoﬂuorescence staining, using commercial
slides coated with ﬁxed human epithelioma type 2
(HEp-2) cells (Immuno Concepts, USA), and ﬂuorescein
isothiocyanate (FITC)-conjugated anti-human IgG anti-
body (The Binding Site, UK) were performed according to
the manufacturer’s instructions.
Evaluation of Intrathecal Ab Production
An IgG index was calculated (Link and Tibbling, 1977;
Lefvert and Link, 1985) as follows: IgG index ¼ (CSF
IgG/serum IgG)/(CSF albumin/serum albumin). An IgG
index .0.7 is accepted as an indication for the intrathecal
Ab’s production (Link and Tibbling, 1977; Lefvert and
Link, 1985).
Measurements of Neuronal Death Caused by Serum or
CSF of RE Patients
Cultures of rat hippocampal neurons (7–10 days old) were
grown as described (Brann et al., 2002). Serum or CSF
(diluted 1:10) of RE patients and of age-matched
neurologically healthy control individuals were ﬁrst
purged (by repetitive ﬁltration through 30–50kDa
vivaspin ﬁlters, as described by Levite and Hermelin
(1999), Levite et al. (1999)) of glutamate and of additional
small molecules (to eliminate their potential contribution
to neuronal death), and then added to the neuronal
cultures. After 18h (378C, humidiﬁed incubator), live and
dead neurons were distinguished using a Live/Dead
w
viability/cytotoxicity kit (Molecular Probes, USA) as
described (Brann et al., 2002).
Functional Hemispherotomy
A functional peri-insular hemispherotomy was performed
according to Villemure’s technique (Villemure and
Mascott, 1995). This operation, a variant of functional
hemispherotomy for epilepsy, allows complete disconnec-
tion of the diseased hemisphere, while removing certain
brain regions, including the temporal opercula and white
matter, cortex, temporal gyrus, amygdala, 5–10mm
insular cortex, and frontobasal cortex and white matter
(Villemure and Mascott, 1995). Thus, an extensive
disconnection of the epileptic area was achieved, but
most of the inﬂammatory parenchyma was left in the
cranium with functional vascularisation.
The Neurological Condition of RE Patients No. 1 and 6,
Before and After Functional Hemispherotomy
RE patient no. 1 (female, age of nine years) was referred
for surgery following 20 months of disease progression,
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the right hand function. She underwent functional peri-
insular hemispherotomy according to the Villemure’s
technique (Villemure and Mascott, 1995). There were no
peri- or post-operative complications. Hemiplegia was
transiently aggravated immediately after surgery. Later,
the patient had no more seizures, epilepsia partialis
continua disappeared and the anti-epileptic drug
treatment was limited to valproic acid alone. The
patient is currently walking with a slight right
hemiparesis, and is progressively regaining some
function of the proximal part of her right arm. She is
also recovering some speech, comprehension and oral
expression.
RE patient no. 6 (female, age of 15 years) underwent
functional hemispherotomy on the right side using
the same surgical procedure. She had a history of partial
seizures since the age of 10 years, and of progressive left
hemiparesis with cognitive deterioration from the age of
14. Leftsided epilepsia partialis continua started six
months before surgery and was refractory to conventional
AEDs as well as to high-dose corticosteroids. The surgical
outcome was excellent. When evaluated one year later, the
patient was seizure-free on carbamazepine alone. Walking
was possible without assistance, and cognitive functions
were improved.
Statistical Analysis
For comparing quantitative variables among the different
groups of epilepsy patients (Figs. 1 and 4), the non-
parametric Kruskal–Wallis test was used. Pairwise
FIGURE 1 Eepilepsy patients with RE or other types of epilepsy harbor signiﬁcantly elevated levels of anti-GluR3B Ab’s. Anti-GluR3b Ab’s were
measured in the sera of six RE patients and of 71 patients with other types of epilepsy (A, 1:100 dilution) and in CSF of four RE patients (B, 1:10).
The horizontal lines represent the medianvalues. Serum anti-GluR3BAb levels were considered elevated when exceeding the mean þ 2*SD of the anti-
GluR3B Ab’s levels in 49 neurologically healthy controls (dashed line). Numbers (RE1–RE6) relate to individual RE patients. Statistical analysis:
(A)KWstatistic ¼ 19:937,p ¼ 0:0005;Kruskal–Wallistest; pairwisecomparisons wereperformedwithMann-Whitney Utest,the pvaluespresented in
the ﬁgure; (B) RE vs. controls U 2 statistic ¼ 0:0; p ¼ 0:0061; Mann-Whitney U-test.
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Mann-Whitney U-test (the respective p-values reﬂect
Bonferrani corrections). Formal statistical analysis of the
results illustrated in Figs. 2 and 3B could not be performed
due to a small number of samples. The clinical evaluation
of the results presented in Fig. 5A–F (using commercially
available diagnostic kits) was based on the manufacturer’s
guidelines and not on formal statistical analysis. All the
statistical analysis was carried out using Macintosh InStat-
GraphPad Software, Version 2.01.
The statistical analysis was performed in collabor-
ation and under the instruction of Professor David
Steinberg, head of the department of Statistics and
Operations Research, School of Mathematical Sciences,
Tel Aviv University, and of Dr. Pnina Lilos, Tel Aviv
University.
RESULTS
Anti-GluR3B Ab’s are Present on both Sides of the
Blood–brain Barrier (BBB) of RE Patients, and in the
Serum of some Patients with other Types of Epilepsy
We tested for speciﬁc anti-GluR3B Ab’s in epilepsy
patients by measuring, in parallel, speciﬁc binding of
serum/CSF to the GluR3B peptide (aa 372–395 of the
ionotropic glutamate receptor of the AMPAsubtype 3) and
nonspeciﬁc binding to BSA. The ﬁnal value of speciﬁc
anti-GluR3B Ab’s was calculated for each individual
separately as (speciﬁc-binding to GluR3B—nonspeciﬁc-
binding to BSA). Using this methodology we found
signiﬁcantly elevated levels of speciﬁc anti-GluR3B Ab’s
in the sera of ﬁve of six RE patients, compared to 49
neurologically healthy control individuals (Fig. 1A). The
difference between the anti-GluR3B Ab levels in the RE
patients and controls was statistically signiﬁcant ðU 2
statistic ¼ 23:00; p ¼ 0:0018; Mann-Whitney U-test).
Elevated levels of anti-GluR3B Ab’s were also detected
in the sera of 17 of 71 (24%) patients with other types of
epilepsy (see “Methods” section; U 2 statistic ¼ 1222:0;
p ¼ 0:0116; Mann-Whitney U-test), conﬁrming and
extending the notion that anti-GluR3B Ab’s are neither
speciﬁc nor restricted to RE (Wiendl et al., 2001;
Mantegazza et al., 2002).
If indeed anti-GluR3 Ab’s play a role in epilepsy, one
ought to ﬁnd them within the CNS, and not only in the
serum. Testing the CSF samples available from only four
RE patients, we found that all had signiﬁcantly elevated
CSF levels of anti-GluR3B Ab’s, as compared to seven
control CSF samples (Fig. 1B, U 2 statistic ¼ 0:0; p ¼
0:0061; Mann-Whitney U test). Thus, the RE patients
studied herein have anti-GluR3B Ab’s on both sides of
their BBB.
Is there an Intrathecal Production of Ab’s in RE
Patients?
In principle, Ab’s found in brain ﬂuids of patients are
either produced intrathecally or ooze from blood into
the brain ﬂuids across a leaky or damaged BBB.
To investigate the possible intrathecal production
of Ab’s in the RE patients found positive for anti-
GluR3B Ab’s in the CSF (Fig. 1B), we adopted the
commonly-accepted calculation of the IgG index ¼
ðCSF IgG=serum IgGÞ=ðCSF albumin=serum albuminÞ:
An IgG index value .0.7 is indicativeof an intrathecal Ab
production (Link and Tibbling, 1977; Lefvert and Link,
1985). The IgG index was calculated only for three of the
four RE patients, from whom CSF samples were available.
The results showed that RE patient no. 1 (RE1, Fig. 1B)
had an IgG index value of 2.6 at the onset of the disease,
and of 1.3 a year later, suggesting an intrathecal
production of Ab’s (regardless of their speciﬁcity).
In contrast, RE patients no. 2 and 6 (RE2 and RE6,
Fig. 1B) had IgG index values of 0.52 and 0.62
FIGURE 2 Anti-GluR3B Ab’s decrease in the CSF of two RE
patients after hemispherotomy. Mean ^ SD of anti-GluR3B Ab’s in CSF
(1:10 dilution) of RE patients no. 1 (A) and 6 (B), before and after
functional hemispherotomy. The corresponding neurological condition of
these RE patients before and after the hemispherotomy appears in the
methods.
POTENTIALLY PATHOGENIC AUTOANTIBODIES 245respectively, arguing against an intrathecal Ab’s pro-
duction. Thus, in some RE patients there is an indication
for intrathecal Ab production, while in others not.
Anti-GluR3B Ab’s Levels Decrease in the CSF of Two
RE Patients after Beneﬁcial Hemispherotomy
We reasoned that if the seizures in RE patients may be
genuinely associated either directly or indirectly with the
presence of anti-GluR3B Ab’s in the CSF, the seizure
decline/arrest after functional hemispherotomy, often
observed in RE patients, should be accompanied by a
parallel decrease in CSF anti-GluR3B Ab levels. To test
this hypothesis, we compared the levels of anti-GluR3B
Ab’s in the CSF of two RE patients before and after
hemispherotomy. For both RE patients (no. 1 and 6), the
functional hemispherotomy was accompanied by seizure
arrest and by a marked neurological improvement
(see “Methods” section). Herein, we found that in both
cases, the hemispherotomy was also followed by
a dramatic reduction of anti-GluR3B Ab’s in the CSF
(Fig. 2). Possible reasons for such a decrease in the levels
of anti-GluR3B Ab’s in brain ﬂuids after hemispherotomy
are raised in the discussion.
Serum and CSFof some RE Patients Kill Hippocampal
Neurons
Neuronal death is a major feature underlining the brain
pathology of RE patients (Rasmussen et al., 1958). To test
the possibility that anti-GluR3B Ab’s (and possibly other
Ab’s) found in RE patients may kill neurons, as we
previously found for mouse anti-GluR3B Ab’s (Levite
etal.,1999), we measuredthe extentofneuronal cell death
uponexposureofculturedhippocampalneuronstoseraand
CSF of anti-GluR3B Ab-positive RE patients, and to sera
andCSFofcontrols(Fig.3A).Ofnote,beforetheiraddition
to the neuronal cultures, the sera/CSF were purged from
small molecules such as glutamate, in order to eliminate
theirpossiblecontributiontoneuronaldeathandretainonly
.50kDa high molecular weight molecules alike IgGs.
We found that the sera of RE patients no. 5 and 6 killed
82 and 97% of the cultured hippocampal neurons,
respectively, compared to 37% death in untreated cultures,
and 29% death in cultures exposed to control sera
(Fig. 3B). Of note, the only common Ab’s shared by RE
patients no. 5 and 6 are the anti-GluR3B Ab’s (see the
summary of the ﬁndings in Fig. 5J). Importantly, the pre-
hemispherotomy CSF of RE patient no. 6 also consistently
killed 50–55% neurons, whereas the control CSF in all
experiments, but one, had no neurotoxic effect (data not
shown). Due to insufﬁcient amounts of post-hemi-
spherotomy CSF from RE patient no. 6, we could
unfortunately not evaluate its ability to kill neurons.
The tests of the neuropathogenic potential of the sera
and CSF of the other RE patients led to inconclusive
results, inasmuch as some samples induced neuronal cell
death while others did not. This could be due to the fact
that samples were withdrawn from patients at different
time points, under the inﬂuence of different medications,
or for unknown reasons.
Anti-dsDNA Ab’s are Found on both Sides of the BBB
of some RE Patients, and in the Sera of Patients with
other Types of Epilepsy
Do RE patients harbor, in addition to anti-GluR3B Ab’s,
other potentially-pathogenic autoimmune Ab’s found
characteristically in “classical” autoimmune diseases?
For the several reasons listed below, we focused ﬁrst our
FIGURE 3 The serum of some RE patients kills neurons. (A) Cultures of rat hippocampal neurons were either left untreated, or exposed to serum (1:10
dilution) of anti-GluR3B positive RE patients no. 5 and 6, and of neurologically healthy controls, after being purged of , 50kDa molecules. The results
(B) represent the mean percentage ^SD of dead hippocampal neurons in two independent experiments, using independent neuronal cultures; 500–800
neurons were counted per coverslip, and two coverslips were analyzed for each sample.
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SLE and are known to cause immune complexes and
tissue damage (Hahn, 1998). Interestingly, an RE patient
whodevelopedSLEwasrecentlyreported(Lascellesetal.,
2002), and from the “other side of the coin”: 7–8% of SLE
patients suffer from epilepsy (and other neurological
complications) (Toubi et al.,1995; Sanna et al., 2003). We
also previously observed that mice immunized with
the GluR3B peptide developed not only the corresponding
anti-GluR3B Ab’s, but also anti-DNA Ab’s (Levite and
Hermelin, 1999; Levite et al., 1999).
TestinghereintheseraofsixREpatientsandof69patients
withother types ofepilepsy,wefoundsigniﬁcantlyelevated
levelsofanti-dsDNAAb’sintheseraoftwoREpatients,and
in the sera of 12 of 69 (17%) patients with other epilepsies
(Fig. 4A). Importantly, the two RE patients, no. 5 and 2,
found with elevated levels of anti-dsDNA Ab’s in their
serum, also harbored elevated levels of such Ab’s in their
CSF (Fig. 4B). To the best of our knowledge, this is the ﬁrst
demonstration of anti-dsDNA Ab’s in the serum, and more
importantly in brain ﬂuids of epilepsy patients.
The Sera of RE Patients contain Additional
Potentially-pathogenic Ab’s Typical of “Classical”
Autoimmune Diseases
Table I summarizes the additional autoimmune Ab’s tested
in this study, the speciﬁc autoantigens they recognize,
theautoimmunediseasesinwhichtheyarecharacteristically
found, and some of their known pathogenic activities in
peripheral organs and in the nervous system of humans
and/or animal models.
FIGURE 4 EpilepsypatientswithREorothertypesofepilepsyharborsigniﬁcantlyelevatedlevelsofanti-dsDNAAb’s.Anti-dsDNAAb’sweremeasured
in sera of six REpatients and of 69 patients with other types of epilepsy (A, 1:100 dilution) and in CSF offour RE patients (B, 1:10).The results present the
mean OD of three independent experiments (horizontal lines- medianvalues). Serum levels were considered elevated when exceeding the mean þ 2*SD of
anti-dsDNA Ab level in 45 neurologically healthy controls (dashed line). RE ¼ Rasmussen’s encephalitis, numbers relate to individual patients. Statistical
analysis: (A) KW-statistic ¼ 20.578, p ¼ 0:0004, Kruskal–Wallis test; pairwise comparisons were performed with the Mann-Whitney U-test, the p values
presentedintheﬁgure;(B)ComparingtheREgrouptothecontrolgroupshowedthatthelevelsofanti-dsDNAAb’sintheCSFwerenotstatisticallydifferent
(U-statistic ¼ 4.0000, p ¼ 0:1905; Mann-Whitney U-test), but elevated levels of anti-dsDNA Ab’s were detected in two RE patients (no. 5 and 2).
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Y. GANOR et al. 248The results obtained herein for the six RE patients are
summarized in Fig. 5J.
In speciﬁc, we found that the sera of some RE
patients contain elevated levels of anti-GAD IgG
(Fig. 5A), anti-cardiolipin IgG (Fig. 5B), anti-b2GPI
IgM and IgG (Fig. 5C, D), and anti-nuclear (ANA) IgG’s
directed against RNP-70 (Fig. 5E) and SS-A (Fig. 5F).
The presence of ANA in the serum was further conﬁrmed
by nuclear immunostaining of ﬁxed HEp-2 cells
(Fig. 5G–I). It is noteworthy that autoimmune Ab’s of
the IgG isotype, as found in the RE patients, are found
characteristically only in patients at the progressive
FIGURE 5 Some RE patients have additional potentially-pathogenic autoimmune ab’s in their serum. (A–F) Levels of anti-GAD IgG (A), anti-
cardiolipin IgG (B), anti-b2GPI IgM (C) and IgG (D), and anti-nuclear antigens RNP-70 IgG (E) and SS-A IgG (F) in sera of six RE patients. The levels
of all the above Ab’s were measured with commercially-available diagnostic kits commonly used in hospitals worldwide (see “Methods” section).
Negative and positive controls and threshold values were supplied by the manufacturers (see “Methods” section). The results represent the mean
concentration of the respective Ab in serum (1:100 dilution) of one experiment, out of total three performed (horizontal lines- medianvalues). Ab levels
were considered clinically elevated when exceeding the numeric clinical threshold indicated by the manufacturer (dashed lines). (G-I)
Immunoﬂuorescence stainingof HEp-2 cells for visual conﬁrmation of ANA: serum of ANA-positiveRE patient no. 1 (H), ANA-negative RE patient no.
3 (G), and ANA-positive control included in the diagnostic kit (I). (J) Summary of clinical information regarding the six RE patients included in this
study and of the ﬁndings regarding the various Ab’s detected in their serum and CSF.
POTENTIALLY PATHOGENIC AUTOANTIBODIES 249stages of the respective autoimmune disease, often in
good correlation with the clinical status of the patients
(e.g. see Carreras et al. (2000)).
No clinically signiﬁcant levels of Ab’s directed against
either GAD, cardiolipin, b2GPI or nuclear antigens were
detected in the CSF of the four RE patients tested (data not
shown).
DISCUSSION
The salient ﬁndings of the present study are as follows: (1)
29% (22 of 77) of patients with different types of epilepsy
have signiﬁcantly elevated levels of anti-GluR3B Ab’s in
serum. These results show that anti-GluR3BAb’s are more
frequent among epilepsy patients than originally assumed,
and that they are neither restricted nor speciﬁc to RE. This
notion is in line with previous studies (Wiendl et al., 2001;
Mantegazza et al., 2002). Importantly, anti-GluR3B Ab’s
may be present both in the serum and in brain ﬂuids (as
observed herein for four RE patients). Thus, some patients
with epilepsy may harbor anti-GluR3B Ab’s on both sides
of their BBB; (2) Following functional hemispherotomy
(performed to two of the RE patients studied herein), anti-
GluR3B Ab levels in the CSF may drop markedly,
together with seizure arrest and neurological improve-
ment. These ﬁndings suggest that in epilepsy patients
undergoing functional hemispherotomy, the high seizure
frequency and impaired neurological condition pre-
surgery, and the improvement in both features post
surgery, may be somehow related to the level of anti-
GluR3B Ab’s in the CSF before and after this brain
operation (i.e. high and low, respectively); (3) Sera and
CSF of RE patients rich in anti-GluR3B Ab’s can kill
hippocampal neurons. If anti-GluR3B Ab’s indeed do so
in vivo (which remains to be shown directly), this may
certainly add to the overall pathology observed in brains
of RE patients; (4) 19% (14 of 75) of patients with
different types of epilepsy contain signiﬁcantly elevated
levels of anti-dsDNA Ab’s. Such anti-dsDNA Ab’s may
be found both in serum and in brain ﬂuids (as found herein
for two RE patients). Characteristically, elevated levels of
anti-dsDNA Ab’s, which are known to cause tissue
damage, are found almost exclusively in serum of SLE
patients. To the best of our knowledge, this is the ﬁrst
demonstration of elevated anti-dsDNA Ab’s within the
serum, and more importantly brain ﬂuids, of patients with
epilepsy; (5) Some epilepsy patients, as found in this study
for the RE patients, may also contain clinically elevated
levels of anti-self IgG’s, directed against GAD, cardio-
lipin, b2GPI, RNP-70 and SS-A. All these autoimmune
Ab’s can exert pathogenic effects once present in the brain
or in the peripheral organs (see Table I).
Collectively, all the above ﬁndings suggest that some
epilepsy patients may have a kaleidoscope of potentially
detrimental anti-self Ab’s on both sides of the BBB, which
in principle could contribute to the epilepsy and the
associated brain pathology. These observations and
suggestions are in line with the ﬁndings of other anti-
self Ab’s, such as anti-Munc 18 Ab’s (Yang et al., 2000)
and anti-NMDA receptor Ab’s, in the serum and CSF of
patients with epilepsia partialis continua (EPC)/RE
(Takahashi et al., 2003).
A still unresolved issue is what causes the production of
the anti-self Ab’s in some of the epilepsy patients.
At present, we can only speculate that this autoimmunity
might be a consequence of either a speciﬁc or a non-
speciﬁc “irritation” of the immune system, for example by
certain viruses, bacteria, vaccinations in childhood, food
poisoning, injury, trauma, stress or any other condition.
Such a speculation is strengthened to some extent by a
recent study (Takahashi et al., 2003) claiming that the
“causative or underlying factors” of chronic EPC in 15
patients were infection in ﬁve, vaccination in three,
encephalitis in two, and head trauma in one.
In principle, the presence of anti-GluR3 Ab’s in the
CSF of epilepsy patients could result from an intrathecal
production (as suggested by the IgG index of RE patient
no. 1) or from a translocation of such Ab’s from the
plasma, via a leaky BBB (as suggested by the IgG index
of RE patients no. 2 and 6). Of note, a recent study
ﬁnds no evidence for intrathecal synthesis of anti-
GluR3A (GluR3 aa 274–302) IgG in four RE patients
(Mantegazza et al., 2002).
Another intriguing question concerns the mechanism
by which the level of anti-GluR3 Ab’s decrease in the
CSF after functional hemispherotomy (as shown here for
RE patients no. 1 and 6). Currently and retrospectively,
there is no way to answer this question. Yet, based on the
common knowledge that maintenance of high levels of
Ab’s (regardless of their type, site of production and
context) requires an active ongoing production of these
Ab’s by a potent immune system, and a steady supply of
the respective antigen, one can speculate that the
hemispherotomy might have decreased either one or
even both of these processes. Thus, the brain surgery
might have weakened the overall state of the immune
system in a nonspeciﬁc manner (i.e. caused a transient
immunodepression), and/or might have reduced the
availability of the free GluR3B antigen (for instance by
down regulating the enzymatic cleavage of the short
GluR3B peptide from its parent receptor: GluR3
(Gahring et al., 2001)). Of note, we recently found that
full length GluR3 is expressed not only on neurons and
glia, but also in high levels on human T-cells (Ganor
et al., 2003). On top of these two hypothetical reasons
which might have caused the drastic decrease of anti-
GluR3B Ab’s after the hemispherotomy, one could
suggest an additional, more trivial explanation, whereby
the drainage of CSF during surgery may have diluted the
anti-GluR3B Ab’s. Of note, by discussing our ﬁndings
and suggestions regarding the levels of anti-GluR3B Ab’s
before and after hemispherectomy, we by no means claim
that this is the most important factor responsible for the
seizure arrest. Clearly, the most crucial factor for the post-
surgery improvement is the elimination of the seizure
Y. GANOR et al. 250loci. Yet, the possibility that additional autoimmune
factors, and speciﬁcally the decrease in the levels of anti-
GluR3B Ab’s within the brain ﬂuids, might have
contributed to the beneﬁcial outcome, deserves attention
in future studies.
Neuronal death is a characteristic feature in RE
(Rasmussen et al., 1958). Herein, we demonstrate that
sera and CSF of some epilepsy patients (e.g. RE patients
no. 5 and 6), which contain elevated levels of anti-GluR3B
Ab’s, have the ability to kill hippocampal neurons. This is
in line with the previous observations by others and
ourselves that both mouse anti-GluR3B Ab’s and rabbit
anti-GluR3 Ab’s (directed against the 212aa long
extracellular fragment) kill neurons and cause an
inﬂammatory histopathology (Rogers et al., 1994; He
et al., 1998; Levite and Hermelin, 1999; Levite et al.,
1999; Whitney and McNamara, 2000; Koustova et al.,
2001). Yet, the precise type and nature of the human Ab’s
causing neuronal death, the mechanism by which the latter
takes place (i.e. exitotoxicity or complement ﬁxation or
other), and whether the Ab-induced neuronal death leads
necessarily to epilepsy are all still open questions which
await further investigations, preferably to be carried out in
several research centers worldwide, and on a much larger
number of patients.
Finally, despite all the above open issues, even at
present we advise to test for the Ab’s studied herein in
epilepsy patients, especially when confronting severe
intractable patients. We further recommend that upon
ﬁnding patients with signiﬁcantly elevated levels of
autoimmune Ab’s, some modes of immunotherapy should
be considered (for review see Levite and Hart (2002)),
(Rogers et al., 1994; Andrews et al., 1996; Antozzi et al.,
1998; Granata et al., 2003; Takahashi et al., 2003),
preferentially before drastic brain surgery, and perhaps
concomitantly with classical AEDs.
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